Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer (NCT05296421)
Pilot Study to Investigate Targetable Metabolic Pathways Sustaining Pancreatic Cancer and Associated Genomic Alterations
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial investigates the nutrients pancreatic cancers depend on in which to survive and the processes these tumors use (metabolism) to obtain these nutrients. Giving U-13C-glucose during surgery may allow doctors to trace the metabolic activity of pancreatic cancer in research experiments done in the laboratory. These experiments may help researchers understand how cancer cells manage their nutrients when compared to normal pancreatic cells.
Who can join: Review the eligibility criteria below.
Location: Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) — Livingston, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
- Biopsy (PROCEDURE)
- Therapeutic Conventional Surgery (PROCEDURE)
- Uniformly-labeled [13C]glucose (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) — Livingston, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
📞 Contact the Study Coordinator
Phone: (732) 235-5912
Email: howard.hochster@rutgers.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Ductal Adenocarcinoma
- A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — Rochester, New York
- Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) — Kansas City, Kansas
- Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer — Durham, North Carolina
- Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer — Washington D.C., District of Columbia
- A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma — Philadelphia, Pennsylvania
- A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal Adenocarcinoma — Los Angeles, California
Explore by condition: All Pancreatic Ductal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.